Core Insights - Zhongsheng Pharmaceutical's stock price increased by 5.71% on October 22, reaching 19.44 CNY per share, with a trading volume of 938 million CNY and a turnover rate of 6.51%, resulting in a total market capitalization of 16.523 billion CNY. The stock has risen for three consecutive days, with a cumulative increase of 7.61% during this period [1] Company Overview - Guangdong Zhongsheng Pharmaceutical Co., Ltd. is located in Dongguan City, Guangdong Province, and was established on December 31, 2001. The company was listed on December 11, 2009. Its main business involves the research, production, and sales of pharmaceuticals [1] - The revenue composition of Zhongsheng Pharmaceutical includes: Traditional Chinese Medicine sales at 53.03%, chemical drug sales at 38.12%, Chinese medicinal materials and decoction pieces sales at 6.13%, raw materials and intermediates sales at 2.14%, and other sales at 0.58% [1] Fund Holdings - According to data from the top ten holdings of funds, one fund under Debon Fund has a significant position in Zhongsheng Pharmaceutical. The Debon Technology Innovation One-Year Open Mixed A Fund (009432) held 218,900 shares in the second quarter, accounting for 4.78% of the fund's net value, making it the fourth-largest holding. The estimated floating profit today is approximately 229,800 CNY, with a floating profit of 284,600 CNY during the three-day increase [2] - The Debon Technology Innovation One-Year Open Mixed A Fund (009432) was established on November 24, 2020, with a current scale of 59.358 million CNY. Year-to-date returns are 50.53%, ranking 829 out of 8160 in its category; the one-year return is 50.93%, ranking 738 out of 8026; and since inception, the return is 14.51% [2]

Market Overview - The Chinese medicine sector experienced a decline of 0.62% on October 20, with WoHua Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Te Yi Pharmaceutical (002728) with a closing price of 9.34, up 5.30% and a trading volume of 439,400 shares [1] - Zhongsheng Pharmaceutical (002317) closed at 18.20, up 4.30% with a trading volume of 656,100 shares [1] - Panlong Pharmaceutical (002864) closed at 30.76, up 2.84% with a trading volume of 36,600 shares [1] - Conversely, WoHua Pharmaceutical (002107) saw a significant decline of 5.26%, closing at 6.30 with a trading volume of 215,700 shares [2] - Other notable decliners included: - Pianzi Shou (600436) down 4.71% to 187.09 [2] - Zhendong Pharmaceutical (300158) down 2.97% to 6.85 [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 371 million yuan from institutional investors, while retail investors saw a net inflow of 253 million yuan [2] - The net inflow from speculative funds was 117 million yuan [2] Individual Stock Capital Flow - Zhongsheng Pharmaceutical (002317) had a net inflow of 62.17 million yuan from institutional investors, but a net outflow of 74.45 million yuan from retail investors [3] - Te Yi Pharmaceutical (002728) saw a net inflow of 54.06 million yuan from institutional investors, with a net outflow of 40.37 million yuan from retail investors [3] - Yunnan Baiyao (000538) had a net inflow of 9.54 million yuan from institutional investors, but a net outflow of 36.07 million yuan from retail investors [3]

Core Viewpoint - The company is developing innovative small molecule drugs for the treatment of Respiratory Syncytial Virus (RSV) infections, as there are currently no specific treatment options available in the domestic market [1] Group 1: Company Developments - The company has initiated a project focused on small molecule drugs targeting RSV, demonstrating strong antiviral activity against multiple RSV strains, excellent pharmacokinetic properties, and low toxicity [1] - The RSV project is currently in the preclinical research stage, with plans for orderly advancement in development [1] Group 2: Product Information - The company's drug, Angladiwei Tablets (brand name: Anruiwei®), is indicated for the treatment of uncomplicated influenza A in adults, with a recommendation for professional medical guidance on usage [1]

Market Overview - On October 17, the traditional Chinese medicine sector declined by 0.99%, with Tianmu Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Stock Performance - Notable gainers in the traditional Chinese medicine sector included: - Weikang Pharmaceutical: closed at 23.39, up 3.54% with a trading volume of 84,100 shares and a turnover of 26.66 million [1] - Enwei Pharmaceutical: closed at 31.40, up 2.45% with a trading volume of 24,700 shares and a turnover of 78.62 million [1] - Zhongsheng Pharmaceutical: closed at 17.45, up 2.11% with a trading volume of 706,300 shares and a turnover of 1.244 billion [1] - Major decliners included: - Tianmu Pharmaceutical: closed at 18.40, down 5.30% with a trading volume of 120,100 shares and a turnover of 22 million [2] - Jilin Aodong: closed at 20.23, down 3.39% with a trading volume of 226,500 shares and a turnover of 465 million [2] Capital Flow - The traditional Chinese medicine sector experienced a net outflow of 736 million from institutional investors, while retail investors saw a net inflow of 582 million [2][3] - Key stocks with significant capital flow included: - Zhongsheng Pharmaceutical: net inflow of 72.58 million from institutional investors, but a net outflow of 131 million from retail investors [3] - Tianmu Pharmaceutical: net inflow of 19.99 million from institutional investors, with net outflows from both retail and speculative investors [3]

Group 1 - The core viewpoint of the news is that Zhongsheng Pharmaceutical experienced a stock price increase of 5.09%, reaching 17.96 CNY per share, with a trading volume of 733 million CNY and a turnover rate of 5.46%, resulting in a total market capitalization of 15.265 billion CNY [1] - Zhongsheng Pharmaceutical, established on December 31, 2001, and listed on December 11, 2009, is primarily engaged in the research, production, and sales of pharmaceuticals. The revenue composition includes 53.03% from traditional Chinese medicine sales, 38.12% from chemical drug sales, 6.13% from Chinese medicinal materials and decoction pieces, 2.14% from raw materials and intermediates, and 0.58% from other sources [1] Group 2 - From the perspective of fund holdings, one fund under Debang Fund has a significant position in Zhongsheng Pharmaceutical. The Debang Technology Innovation One-Year Open Mixed A Fund (009432) held 218,900 shares in the second quarter, accounting for 4.78% of the fund's net value, making it the fourth-largest holding. The estimated floating profit today is approximately 190,400 CNY [2] - The Debang Technology Innovation One-Year Open Mixed A Fund (009432) was established on November 24, 2020, with a latest scale of 59.358 million CNY. Year-to-date returns are 44.95%, ranking 1217 out of 8160 in its category; the one-year return is 63.3%, ranking 591 out of 8021; and since inception, the return is 10.26% [2]

Group 1 - The core point of the news is that Zhongsheng Pharmaceutical experienced a slight decline in stock price and had notable changes in financing activities on October 16, with a net financing outflow of 657.69 million yuan [1] - As of October 16, the total financing and securities lending balance for Zhongsheng Pharmaceutical was 493 million yuan, with a financing balance of 491 million yuan, accounting for 3.38% of the circulating market value, indicating a relatively high level compared to the past year [1] - The company reported a decrease in operating income for the first half of 2025, amounting to 1.3 billion yuan, a year-on-year decline of 4.74%, while the net profit attributable to the parent company increased significantly by 114.96% to 188 million yuan [2] Group 2 - Zhongsheng Pharmaceutical has distributed a total of 2.019 billion yuan in dividends since its A-share listing, with 502 million yuan distributed over the past three years [3] - As of June 30, 2025, the number of shareholders for Zhongsheng Pharmaceutical was 89,900, a decrease of 1.32% from the previous period, while the average circulating shares per person increased by 1.33% to 8,470 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest shareholder with 9.1731 million shares, marking a new entry, while other funds have reduced their holdings [3]

Core Viewpoint - The company is actively pursuing international market opportunities and is focused on the commercialization of its innovative drugs, particularly the antiviral drug Anladiwei and the RAY1225 injection for obesity and type 2 diabetes treatment [2]. Group 1: Company Performance - As of October 14, 2025, the stock price of Zhongsheng Pharmaceutical (002317) closed at 16.56 yuan, down 1.02%, with a turnover rate of 3.3%, trading volume of 251,100 shares, and a transaction amount of 422 million yuan [1]. Group 2: Product Development and Market Strategy - The company is advancing the commercialization of Anladiwei, which has shown strong inhibitory activity against various strains of influenza viruses, including those resistant to existing treatments [2]. - The RAY1225 injection is in Phase III clinical trials, showing significant improvements in weight loss, blood sugar reduction, and various cardiovascular and metabolic risk factors compared to placebo [2]. - The company is also progressing with the Phase III clinical trial of Anladiwei granules for children, having received ethical approval [2]. Group 3: Market Dynamics and Investor Relations - On October 14, the net inflow of main funds was 4.27 million yuan, while speculative funds saw a net inflow of 9.01 million yuan, and retail investors experienced a net outflow of 13.29 million yuan [2]. - The company is closely monitoring the dynamics of disease outbreaks and is prepared for production and sales during the flu season [2]. - The company is actively engaging in negotiations for the inclusion of Anladiwei in the annual medical insurance directory to benefit more patients [2].

Core Viewpoint - The company is actively advancing the Phase III clinical trial of RAY1225 injection for treating obesity/overweight patients and those with type 2 diabetes, showing promising results in earlier trials [1] Group 1: Clinical Trial Progress - The Phase III clinical trial of RAY1225 injection is currently in progress [1] - The Phase II clinical trial results indicate that RAY1225 injection significantly outperforms the placebo in weight loss, blood sugar reduction, and improvement of various cardiovascular-renal-metabolic risk factors [1]

Core Viewpoint - Zhongsheng Pharmaceutical (002317) announced that the RAY1225 injection's Phase II clinical trial met all primary endpoints and achieved favorable topline analysis results, indicating that the trial results are ideal and meet expectations [1] Group 1 - The RAY1225 injection is currently advancing to Phase III clinical trials for the treatment of obesity/overweight patients and patients with type 2 diabetes [1]

Core Viewpoint - The Chinese Medicine ETF (560080) has shown resilience despite a recent market downturn, with significant capital inflow and a leading position in its category [1][7]. Market Performance - The Chinese Medicine ETF (560080) experienced a nearly 1% decline after a significant opening drop, with a total trading volume exceeding 110 million yuan [1]. - The ETF has seen a net inflow of over 170 million yuan in the last 10 days, bringing its total size to nearly 2.4 billion yuan, leading its peers [1]. Component Stocks - Most component stocks of the Chinese Medicine ETF (560080) closed in the red, with notable declines including Jilin Aodong (-1.44%), Yunnan Baiyao (-1.01%), and Dong'e Ejiao (-1.22%) [3][4]. Yearly Index Performance - The Chinese Medicine Index has shown negative returns year-to-date, with a decline of 3.27% this year and an 8.13% drop in 2024, marking a four-year streak of negative annual performance [4]. Valuation Metrics - The TTM price-to-earnings ratio for the Chinese Medicine ETF (560080) stands at 25.11, which is at the 22.28% percentile of the past decade, indicating a more favorable valuation [6]. Leverage and Financing - Financing activities remain robust, with the latest financing balance for the ETF exceeding 84 million yuan, maintaining historical highs [7]. Industry Outlook - According to CITIC Securities, channel adjustments in the Chinese medicine sector are nearing completion, with expectations for demand recovery in the fourth quarter [9]. - The demand for traditional Chinese medicine products is anticipated to stabilize, with a gradual recovery expected as external pressures ease [9]. New Drug Developments - The number of new drug applications in the Chinese medicine sector is on the rise, with 92 new IND applications and 42 NDA applications reported in the first nine months of 2025 [10][12]. - Recent approvals for new drugs from companies like Fangsheng Pharmaceutical and Tianzhihui are expected to contribute positively to their growth [12].